+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Peptide Drug Conjugates Market Size, Share & Trends Analysis Report By Product (Lutetium, Melflufen, ANG1005, BT1718, CBX-12, Other Pipeline), By type (Diagnostic, Therapeutic), By Region, And Segment Forecasts, 2023 - 2030

  • PDF Icon

    Report

  • 80 Pages
  • September 2023
  • Region: Global
  • Grand View Research
  • ID: 5702099
Description Jump to:
The global peptide drug conjugates market is expected to reach USD 4.21 billion by 2030, registering CAGR of 28.58% during the forecast period. The growth of market is attributed to the global upsurge in cancer cases and related mortality, strong clinical trial pipeline with peptide drug conjugates (PDCs) and associated side effects of the existing products such as uncontrolled toxicity associated with small molecule chemotherapeutic agents.

According to WHO, cancer is the leading cause of disease related deaths, worldwide. In 2020, around 10.0 million deaths globally and more than 6.0 million deaths in the U.S. were recorded due to the cancer. Furthermore, as per cancer.gov, by 2040, the new cancer cases patients per year is estimated to reach to 29.0 million and the number of cancer-related deaths to 16.0 million. Therefore, rising demand for the novel treatment like PDCs to target uncontrolled cell growth is expected to fuel the peptide drug conjugates market growth.

Currently, Lutathera (Lu 177 dotatate) and Pepaxto (Melflufen) are the two FDA approved PDCs to treat uncontrolled cell growth. The marketplace has the FDA approved PDC as the Novartis’s Lutathera (lutetium Lu 177)indicated for somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors in adults. Later, in February 2021, Oncopeptides ABs announced the FDA’s accelerated approval for Pepaxto (Melphalan) indicated for the treatment in multiple myeloma. Presence of limited PDCs in space in offering remunerative opportunity for the growth.

Furthermore, presence of robust clinical trial pipeline and expected launch of new PDCs is anticipated to boost the market growth during the forecast period. These can attribute due to the PDC ANG1005 under phase 3 clinical studies for brain tumor, and PDCs BT5528 and BT1718 under phase 2 to clinical studies for lung cancer. CBX-12 is another phase 2 PDC candidate indicated for the small cell lung cancer treatment.

Key players are undertaking strategic initiatives such as collaborations, merger & acquisitions, agreements, along with financial investments, which is driving the market growth. For instance, in December 2021, Coherent Biopharma and WuXi STA announced the strategic partnership agreement to develop their current and future therapeutic drugs including peptide drug conjugates.

Peptide Drug Conjugates Market Report Highlights

  • By product, Lutathera segment accounted for the largest share of the market in 2022 due to the first approved PDC and global rise in cancer patients which is offering high demand for these medicines
  • Based on type, the therapeutic segment dominated the peptide drug conjugates market in 2022 owing to the presence of both approved PDCs, Lutathera and Pepaxto as therapeutic agents targeting tumor cells
  • North America dominated the global market in 2022 owing to the factors such as an increase in new cancer cases along with related complexity and high awareness among healthcare professionals about novel therapies

Table of Contents

Chapter 1 Methodology and Scope
1.1 Market Segmentation
1.1.1 Regional Scope
1.1.2 Market Definitions
1.1.3 Estimates and Forecast Timeline
1.2 Objectives
1.2.1 Objective - 1
1.2.2 Objective - 2
1.2.3 Objective - 3
1.3 Research Methodology
1.4 Information Procurement
1.4.1 Purchased Database
1.4.2 Internal Database
1.4.3 Secondary Sources
1.4.4 Primary Research
1.4.5 Details of Primary Research
1.5 Information or Data Analysis
1.5.1 Data Analysis Models
1.6 Market Formulation & Validation
1.7 Model Details
1.7.1 Commodity Flow Analysis
1.7.1.1 Approach 1: Commodity Flow Approach
1.7.1.2 Approach 2: Country wise market estimation using bottom-up approach
1.8 List of Secondary Sources
1.9 List of Abbreviations
Chapter 2 Executive Summary
2.1 Market Snapshot
2.2 Product and Type Segment Snapshot
2.3 Competitive Landscape Snapshot
Chapter 3 Peptide Drug Conjugates Market Variables, Trends, and Scope
3.1 Peptide Drug Conjugates Market Lineage Outlook
3.1.1 Parent Market Outlook
3.2 Market Dynamics
3.2.1 Market Driver Analysis
3.2.1.1 Rising Cancer Prevalence and Related Mortality
3.2.1.1.1 Cancer Incidence Data
3.2.1.2 Robust Clinical Trial Pipeline
3.2.2 Market Restraint Analysis
3.2.2.1 Long R&D Time and Slow Clinical Development Process
3.3 Peptide Therapeutics Market Analysis Tools
3.3.1 Porter’s Five Forces Analysis
3.3.2 PESTLE Analysis
3.4 Pipeline Analysis
Chapter 4 Peptide Drug Conjugates Market - Segment Analysis, by Type, 2018 - 2030 (USD Million)
4.1 Peptide Drug Conjugates Market: Type Movement Analysis
4.2 Peptide Drug Conjugates Market Estimates & Forecast, By Type (USD Million)
4.2.1 Therapeutics
4.2.2 Diagnostics
Chapter 5 Peptide Drug Conjugates Market - Segment Analysis, by Product, 2018 - 2030 (USD Million)
5.1 Peptide Drug Conjugates Market: Product Movement Analysis
5.2 Peptide Drug Conjugates Market Estimates & Forecast, By Product (USD Million)
5.2.1 OctreoScan
5.2.2 Lutathera
5.2.3 Pepaxto/ Melflufen
5.2.4 ANG1005
5.2.5 BT1718
Chapter 6 Peptide Drug Conjugates Market: Regional Estimates and Trend Analysis by Product and Type, 2018 - 2030 (USD Million)
6.1 Peptide Drug Conjugates Market: Regional Outlook
6.2 North America
6.2.1 North America Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.2.2 U.S.
6.2.2.1 Key Country Dynamics
6.2.2.2 Target Disease Prevalence
6.2.2.3 U.S. Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.2.2.4 Competitive/Market Scenario
6.2.2.5 Regulatory Framework
6.2.2.6 Reimbursement Scenario
6.2.3 Canada
6.2.3.1 Key Country Dynamics
6.2.3.2 Target Disease Prevalence
6.2.3.3 Canada Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.2.3.4 Competitive/Market Scenario
6.2.3.5 Regulatory Framework
6.2.3.6 Reimbursement Scenario
6.3 Europe
6.3.1 Europe Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.3.2 UK
6.3.2.1 Key Country Dynamics
6.3.2.2 Target Disease Prevalence
6.3.2.3 UK Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.3.2.4 Competitive/Market Scenario
6.3.2.5 Regulatory Framework
6.3.2.6 Reimbursement Scenario
6.3.3 Germany
6.3.3.1 Key Country Dynamics
6.3.3.2 Target Disease Prevalence
6.3.3.3 Germany Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.3.3.4 Competitive/Market Scenario
6.3.3.5 Regulatory Framework
6.3.3.6 Reimbursement Scenario
6.3.4 France
6.3.4.1 Key Country Dynamics
6.3.4.2 Target Disease Prevalence
6.3.4.3 France Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.3.4.4 Competitive/Market Scenario
6.3.4.5 Regulatory Framework
6.3.4.6 Reimbursement Scenario
6.3.5 Spain
6.3.5.1 Key Country Dynamics
6.3.5.2 Target Disease Prevalence
6.3.5.3 Spain Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.3.5.4 Competitive/Market Scenario
6.3.5.5 Regulatory Framework
6.3.5.6 Reimbursement Scenario
6.3.6 Italy
6.3.6.1 Italy Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.3.6.2 Competitive/Market Scenario
6.3.6.3 Regulatory Framework
6.3.6.4 Reimbursement Scenario
6.3.7 Denmark
6.3.7.1 Key Country Dynamics
6.3.7.2 Target Disease Prevalence
6.3.7.3 Denmark Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.3.7.4 Competitive/Market Scenario
6.3.7.5 Regulatory Framework
6.3.7.2 Reimbursement Scenario
6.3.8 Sweden
6.3.8.1 Key Country Dynamics
6.3.8.2 Target Disease Prevalence
6.3.8.3 Sweden Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.3.8.4 Competitive/Market Scenario
6.3.8.5 Regulatory Framework
6.3.8.6 Reimbursement Scenario
6.3.9 Norway
6.3.9.1 Key Country Dynamics
6.3.9.2 Target Disease Prevalence
6.3.9.3 Norway Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.3.9.4 Competitive/Market Scenario
6.3.9.5 Regulatory Framework
6.3.9.6 Reimbursement Scenario
6.3.9.7 Rest of Europe Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4 Asia Pacific
6.4.1 Asia Pacific Peptide Drug Conjugates Market Estimates And Forecasts, 2018 - 2030 (USD Million)
6.4.2 Japan
6.4.2.1 Key Country Dynamics
6.4.2.2 Target Disease Prevalence
6.4.2.3 Japan Peptide Drug Conjugates Market Estimates And Forecasts, 2018 - 2030 (USD Million)
6.4.2.4 Competitive/Market Scenario
6.4.2.5 Regulatory Framework
6.4.2.6 Reimbursement Scenario
6.4.3 China
6.4.3.1 Key Country Dynamics
6.4.3.2 Target Disease Prevalence
6.4.3.3 China Peptide Drug Conjugates Market Estimates And Forecasts, 2018 - 2030 (USD Million)
6.4.3.4 Competitive/Market Scenario
6.4.3.5 Regulatory Framework
6.4.3.6 Reimbursement Scenario
6.4.4 India
6.4.4.1 Key Country Dynamics
6.4.4.2 Target Disease Prevalence
6.4.4.3 India Peptide Drug Conjugates Market Estimates And Forecasts, 2018 - 2030 (USD Million)
6.4.4.4 Competitive/Market Scenario
6.4.4.5 Regulatory Framework
6.4.4.6 Reimbursement Scenario
6.4.5 Australia
6.4.5.1 Key Country Dynamics
6.4.5.2 Target Disease Prevalence
6.4.5.3 Australia Peptide Drug Conjugates Market Estimates And Forecasts, 2018 - 2030 (USD Million)
6.4.5.4 Competitive/Market Scenario
6.4.5.5 Regulatory Framework
6.4.6 Thailand
6.4.6.1 Key Country Dynamics
6.4.6.2 Thailand Peptide Drug Conjugates Market Estimates And Forecasts, 2018 - 2030 (USD Million)
6.4.6.3 Competitive/Market Scenario
6.4.6.4 Regulatory Framework
6.4.6.5 Reimbursement Scenario
6.4.7 South Korea
6.4.7.1 Key Country Dynamics
6.4.7.2 South Korea Peptide Drug Conjugates Market Estimates And Forecasts, 2018 - 2030 (USD Million)
6.4.7.3 Competitive/Market Scenario
6.4.7.4 Regulatory Framework
6.4.7.5 Reimbursement Scenario
6.4.7.6 Rest of Asia Pacific Peptide Drug Conjugates Market Estimates And Forecasts, 2018 - 2030 (USD Million)
6.5 Latin America
6.5.1 Latin America Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5.2 Brazil
6.5.2.1 Key Country Dynamics
6.5.2.2 Target Disease Prevalence
6.5.2.3 Brazil Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5.2.4 Competitive/Market Scenario
6.5.2.5 Regulatory Framework
6.5.2.6 Reimbursement Scenario
6.5.3 Mexico
6.5.3.1 Key Country Dynamics
6.5.3.2 Target Disease Prevalence
6.5.3.3 Mexico Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5.3.4 Competitive/Market Scenario
6.5.3.5 Regulatory Framework
6.5.3.6 Reimbursement Scenario
6.5.4 Argentina
6.5.4.1 Key Country Dynamics
6.5.4.2 Target Disease Prevalence
6.5.4.3 Argentina Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5.4.4 Competitive/Market Scenario
6.5.4.5 Regulatory Framework
6.5.4.6 Reimbursement Scenario
6.5.4.7 Rest of Latin America Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6 MEA
6.6.1 MEA Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6.2 South Africa
6.6.2.1 Key Country Dynamics
6.6.2.2 Target Disease Prevalence
6.6.2.3 South Africa Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6.2.4 Competitive/Market Scenario
6.6.2.5 Regulatory Framework
6.6.2.6 Reimbursement Scenario
6.6.3 Saudi Arabia
6.6.3.1 Key Country Dynamics
6.6.3.2 Target Disease Prevalence
6.6.3.3 Saudi Arabia Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6.3.4 Competitive/Market Scenario
6.6.3.5 Regulatory Framework
6.6.3.6 Reimbursement Scenario
6.6.4 UAE
6.6.4.1 Key Country Dynamics
6.6.4.2 Target Disease Prevalence
6.6.4.3 UAE Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6.4.4 Competitive/Market Scenario
6.6.4.5 Regulatory Framework
6.6.4.6 Reimbursement Scenario
6.6.5 Kuwait
6.6.5.1 Key Country Dynamics
6.6.5.2 Target Disease Prevalence
6.6.5.3 Kuwait Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6.5.4 Competitive/Market Scenario
6.6.5.5 Regulatory Framework
6.6.5.6 Reimbursement Scenario
6.6.5.7 Rest of MEA Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 7 Competitive Landscape
7.1 Strategy Mapping
7.1.1 New Launches
7.1.2 Collaboration
7.1.3 Partnership
7.1.4 Others
7.2 Company Profiles
7.2.1 Novartis AG.
7.2.1.1 Company Overview
7.2.1.2 Financial Performance
7.2.1.3 Product Benchmarking
7.2.1.4 Strategic Initiatives
7.2.2 Bicycle Therapeutics
7.2.2.1 Company Overview
7.2.2.2 Financial Performance
7.2.2.3 Product Benchmarking
7.2.2.4 Strategic Initiatives
7.2.3 AstraZeneca
7.2.3.1 Company Overview
7.2.3.2 Financial Performance
7.2.3.3 Product Benchmarking
7.2.3.4 Strategic Initiatives
7.2.4 Cybrexa Therapeutics
7.2.4.1 Company Overview
7.2.4.2 Financial Performance
7.2.4.3 Product Benchmarking
7.2.4.4 Strategic Initiatives
7.2.5 Oncopeptides Inc.
7.2.5.1 Company Overview
7.2.5.2 Financial Performance
7.2.5.3 Product Benchmarking
7.2.5.4 Strategic Initiatives
7.2.6 Angiochem Inc.
7.2.6.1 Company Overview
7.2.6.2 Financial Performance
7.2.6.3 Product Benchmarking
7.2.7 Innovasium Soricimed Biopharma
7.2.7.1 Company Overview
7.2.7.2 Financial performance
7.2.7.3 Product Benchmarking
7.2.7.4 Strategic Initiatives
7.2.8 Theratechnologies
7.2.8.1 Company Overview
7.2.8.2 Financial performance
7.2.8.3 Product Benchmarking
7.2.8.4 Strategic Initiatives
Chapter 8 Conclusion
List of Tables
Table 1 List of Secondary Sources
Table 2 List of Abbreviation
Table 3 List of Parameters
Table 4 List of Distributors
Table 5 Global Peptide Drug Conjugates Market, By Region, 2018 - 2030 (USD Million)
Table 6 Global Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
Table 7 Global Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
Table 8 North America Peptide Drug Conjugates Market, By Country, 2018 - 2030 (USD Million)
Table 9 North America Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
Table 10 North America Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
Table 11 U.S. Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
Table 12 U.S. Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
Table 13 Canada Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
Table 14 Canada Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
Table 15 Europe Peptide Drug Conjugates Market, By Country, 2018 - 2030 (USD Million)
Table 16 Europe Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
Table 17 Europe Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
Table 18 Germany Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
Table 19 Germany Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
Table 20 UK Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
Table 21 UK Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
Table 22 France Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
Table 23 France Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
Table 24 Italy Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
Table 25 Italy Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
Table 26 Spain Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
Table 27 Spain Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
Table 28 Denmark Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
Table 29 Denmark Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
Table 30 Sweden Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
Table 31 Sweden Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
Table 32 Norway Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
Table 33 Norway Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
Table 34 Asia Pacific Peptide Drug Conjugates Market, By Country, 2018 - 2030 (USD Million)
Table 35 Asia Pacific Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
Table 36 Asia Pacific Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
Table 37 Japan Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
Table 38 Japan Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
Table 39 China Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
Table 40 China Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
Table 41 India Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
Table 42 India Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
Table 43 South Korea Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
Table 44 South Korea Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
Table 45 Australia Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
Table 46 Australia Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
Table 47 Thailand Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
Table 48 Thailand Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
Table 49 Latin America Peptide Drug Conjugates Market, By Country, 2018 - 2030 (USD Million)
Table 50 Latin America Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
Table 51 Latin America Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
Table 52 Brazil Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
Table 53 Brazil Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
Table 54 Mexico Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
Table 55 Mexico Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
Table 56 Argentina Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
Table 57 Argentina Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
Table 58 Middle East & Africa Peptide Drug Conjugates Market, By Country, 2018 - 2030 (USD Million)
Table 59 Middle East & Africa Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
Table 60 Middle East & Africa Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
Table 61 Saudi Arabia Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
Table 62 Saudi Arabia Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
Table 63 South Africa Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
Table 64 South Africa Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
Table 65 UAE Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
Table 66 UAE Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
Table 67 Kuwait Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
Table 68 Kuwait Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
List of Figures
Fig. 1 Peptide drug conjugates market segmentation
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Value chain based sizing & forecasting
Fig. 6 QFD modelling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 Market snapshot
Fig. 9 Product and type segment snapshot
Fig. 10 Competitive landscape snapshot
Fig. 11 Peptide Therapeutic Market (USD Billion)
Fig. 12 Market dynamics
Fig. 13 Peptide-drug conjugates against cancer in different developmental phases are listed in the table below
Fig. 14 Global number of new cases caused by top 11 cancer types in 2023 (in thousands)
Fig. 15 Clinical trial pipeline for PDCs
Fig. 16 Porter’s five forces analysis
Fig. 17 PESTLE analysis
Fig. 18 Clinical trials in PDCs
Fig. 19 Peptide therapeutics market: Type outlook and key takeaways
Fig. 20 Peptide therapeutics market: Type movement analysis
Fig. 21 Therapeutics market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 22 Diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 23 Peptide therapeutics market: Product outlook and key takeaways
Fig. 24 Peptide therapeutics market: Product movement analysis
Fig. 25 OctreoScan market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 26 Lutathera market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 27 Pepaxto/Melflufen market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 28 ANG1005 market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 29 BT1718 market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 30 Peptide drug conjugates market revenue, by region, 2022 & 2030, USD Million
Fig. 31 Regional marketplace: Key takeaways
Fig. 32 Regional marketplace: Key takeaways
Fig. 33 North America peptide drug conjugates market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 34 Key Country Dynamics
Fig. 35 Target disease prevalence
Fig. 36 U.S. peptide drug conjugates market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 37 Key Country Dynamics
Fig. 38 Target disease prevalence
Fig. 39 Canada peptide drug conjugates market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 40 Europe peptide drug conjugates market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 41 Key Country Dynamics
Fig. 42 Target disease prevalence
Fig. 43 UK peptide drug conjugates market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 44 Key Country Dynamics
Fig. 45 Target disease prevalence
Fig. 46 Germany peptide drug conjugates market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 47 Key Country Dynamics
Fig. 48 Target disease prevalence
Fig. 49 France peptide drug conjugates market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 50 Key Country Dynamics
Fig. 51 Target disease prevalence
Fig. 52 Spain peptide drug conjugates market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 53 Italy Peptide drug conjugates market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 54 Key Country Dynamics
Fig. 55 Target disease prevalence
Fig. 56 Denmark peptide drug conjugates market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 57 Key Country Dynamics
Fig. 58 Target disease prevalence
Fig. 59 Sweden peptide drug conjugates market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 60 Key Country Dynamics
Fig. 61 Target disease prevalence
Fig. 62 Norway Peptide Drug Conjugates market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 63 Rest of Europe peptide drug conjugates market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 64 Asia Pacific peptide drug conjugates market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 65 Key Country Dynamics
Fig. 66 Target disease prevalence
Fig. 67 Japan peptide drug conjugates market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 69 Target disease prevalence
Fig. 70 China peptide drug conjugates market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 71 Key Country Dynamics
Fig. 72 Target disease prevalence
Fig. 73 India peptide drug conjugates market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 74 Key Country Dynamics
Fig. 75 Target disease prevalence
Fig. 76 Australia peptide drug conjugates market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 77 Key Country Dynamics
Fig. 78 Thailand peptide drug conjugates market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 79 Key Country Dynamics
Fig. 80 South Korea peptide drug conjugates market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 81 Rest of Asia Pacific peptide drug conjugates market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 82 Latin America peptide drug conjugates market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 83 Key Country Dynamics
Fig. 84 Target disease prevalence
Fig. 85 Brazil peptide drug conjugates market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 86 Key Country Dynamics
Fig. 87 Target disease prevalence
Fig. 88 Mexico peptide drug conjugates market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 89 Key Country Dynamics
Fig. 90 Target disease prevalence
Fig. 91 Argentina peptide drug conjugates market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 92 Rest of Latin America peptide drug conjugates market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 93 MEA peptide drug conjugates market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 94 Key Country Dynamics
Fig. 95 Target disease prevalence
Fig. 96 South Africa peptide drug conjugates market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 97 Key Country Dynamics
Fig. 98 Target disease prevalence
Fig. 99 Saudi Arabia peptide drug conjugates market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 100 Key Country Dynamics
Fig. 101 Target disease prevalence
Fig. 102 UAE peptide drug conjugates market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 103 Key Country Dynamics
Fig. 104 Target disease prevalence
Fig. 105 Kuwait peptide drug conjugates market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 106 Rest of MEA peptide drug conjugates market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 107 Key company categorization
Fig. 108 Company market share analysis, 2022
Fig. 109 Strategic framework

Companies Mentioned

  • Novartis Ag.
  • Bicycle Therapeutics
  • Astrazeneca
  • Cybrexa Therapeutics
  • Oncopeptides Inc.
  • Angiochem Inc.
  • Innovasium Soricimed Biopharma
  • Theratechnologies

Methodology

Loading
LOADING...

Related Topics

Related Reports

Antibody Drug Conjugates Market Size, Share & Trends Analysis Report By Application (Blood Cancer, Breast Cancer), By Technology (Type-cleavable, Non-cleavable), By Product, By Target, By Region, And Segment Forecasts, 2024 - 2030 - Product Image

Antibody Drug Conjugates Market Size, Share & Trends Analysis Report By Application (Blood Cancer, Breast Cancer), By Technology (Type-cleavable, Non-cleavable), By Product, By Target, By Region, And Segment Forecasts, 2024 - 2030

  • Report
  • 125 Pages
  • Global
From
Global Bicycle Toxin Conjugates Clinical Trials & Market Opportunity Insight 2024 - Product Image

Global Bicycle Toxin Conjugates Clinical Trials & Market Opportunity Insight 2024

  • Report
  • 50 Pages
  • Global
From
Constrained Peptide Drugs Market by Peptide Type, End-User - Global Forecast 2025-2030 - Product Image

Constrained Peptide Drugs Market by Peptide Type, End-User - Global Forecast 2025-2030

  • Report
  • 183 Pages
  • Global
From
Antibody Drug Conjugates Contract Manufacturing Market by Linker, Condition, End Use - Global Forecast 2025-2030 - Product Image

Antibody Drug Conjugates Contract Manufacturing Market by Linker, Condition, End Use - Global Forecast 2025-2030

  • Report
  • 196 Pages
  • Global
From
Antibody Drug Conjugate - Market Insights, Competitive Landscape, and Market Forecast - 2030 - Product Image

Antibody Drug Conjugate - Market Insights, Competitive Landscape, and Market Forecast - 2030

  • Report
  • 150 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.